Other

Pfizer Corporation

Günther Metz

Renate Sekul

Isabelle Cornut

Klaus Büttner

Jean-Louis Henri Dasseux

Jean Dufourcq

The present invention provides multimeric apoprotein agonists. Pharmaceutical compositions which include a multimeric apoprotein agonist and a pharmaceutically acceptable carrier, excipient or diluent are also provided. These pharmaceutical are useful to treat a variety of disorders associated with dyslipidemia.

Multimeric apoprotein agonists

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

Pharmaceutical compositions of apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Multimeric Apo A-I agonist compounds

Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.

Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Apolipoprotein A-L agonists and their use to treat dyslipidemic disorders

Growing community of inventors

Edingen-Neckarhausen, Germany

Günther Metz